Industry Briefs: June 18, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: June 18, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Amgen has completed its acquisition of the Turkish company, Mustafa Nevzat Pharmaceuticals. Read More

Dalton Pharma Services and Clarity Pharmaceuticals have entered into a manufacturing-services agreement under which Dalton Pharma Services will provide cGMP chemistry manufacturing, scale-up, aseptic fill–finish services, and analytical support for Clarity’s positron emission tomography-based companion diagnostics and radio-immunotherapeutics development program. Read More

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed a commercial agreement for contract manufacturing services using its proprietary XD high cell-density process technology with an undisclosed pharmaceutical company. Read More

In other news, Royal DSM’s tender offer to purchase all outstanding shares of common stock of the medical-device company Kensey Nash at a price of $38.50 per share was successful. Read More

Frazier Healthcare has acquired Catalent Pharma Solutions's US commercial pharmaceutical-packaging operations, based in Philadelphia, Pennsylvania, and Woodstock, Illinois. Read More

JDRF and Novo Nordisk have established an R&D collaboration for disease-modifying immunotherapies for Type I diabetes. Read More

Merck & Co. and Ambrx have agreed to design and develop rationally optimized biologic drug conjugates based on Ambrx’s site-specific protein medicinal chemistry technology. Read More

Roche’s Genentech has entered into a CHF 400-million ($418 million) agreement with AC Immune for developing anti-Tau antibodies for treating Alzheimer’s disease. Read More

Unilife has entered into a seven-year commercial supply contract with an undisclosed pharmaceutical company for the use of its Unifill prefilled syringe. Read More

Waters has began construction on its new mass spectrometry headquarters in Wilmslow, United Kingdom. Read More

People News

AMRI has appointed Srinivas Nanduri as director of medicinal chemistry at the company’s research center in Hyderabad, India, reporting to Subramanyam Maddala, president of AMRI’s India operations. In addition, Suneel Kumar Bommisetty was named senior research associate of computational chemistry, reporting to Nanduri. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here